New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
06:02 EDTAKERAkers Biosciences signs agreements to market rapid tests in India
Akers Biosciences entered into an agreement with Jai Capital, a Nevada company specializing in market development, distribution, and joint ventures of medical devices in India, to market the company's PIFA Heparin/Platelet Factor-4 Rapid Assay, PIFA Dengue Assay, Battlefield Blood Transfusion Card and Tri-Cholesterol rapid tests. Limited initial sales to the military are expected to enable the military to carry out evaluations of the products. The Directors believe that military approval, if obtained, is likely to occur in the second half of the current financial year. Secondly, Jai will seek to forge one or more strategic partnerships with Indian medical diagnostic companies. It is the Directors' opinion that, if formed, these partnerships may help to facilitate a faster approval process for the Company's tests with the Indian Government and as such it is expected that the approval process will start in due course in the event that such strategic partnerships are formed. Unlike with the military, these approvals are necessary to sell the Company's products into the insurance and medical marketplaces in India.
News For AKER From The Last 14 Days
Check below for free stories on AKER the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
05:33 EDTAKERAkers Biosciences signs feasibility study deal with Konica Minolta
Akers Biosciences (AKER) has signed a feasibility study deal with Konica Minolta, Inc. (KNCAY) to develop a rapid test for the early detection of cardiac muscle tissue damage a condition commonly observed in patients suffering myocardial infarction. Heart attacks are the leading cause of death in U.S., with approximately 1.1M Americans suffering heart attacks each year. Konica Minolta, has asked Akers to study a diagnostic test based on Akers' proprietary Particle Immuno Filtration Assay, or PIFA, technology which, if successful, will facilitate the rapid detection of biomarkers present in a blood sample which can be used to identify cardiac muscle tissue damage. Such tissue damage can occur even at the early stages of a heart attack so early diagnosis could have a significant beneficial impact on patient treatment. The PIFA technology, when combined with Akers' proprietary Rapid Blood Cell Separation Technology, seraSTAT, permits the testing of whole blood from a finger prick sample allowing a test to be carried out in minutes at the point of care. Currently available tests for cardiac muscle tissue damage require a blood draw and the use of an interpretation device; and typically take 20-30 minutes to complete in a laboratory. Konica Minolta, at its own cost, has asked Akers to study a test which can be performed in under 10 minutes, using only a small blood sample obtained from a finger stick; and which can be read visually at the point of care.
July 17, 2014
05:47 EDTAKERAkers announces U.S. patent granted for Breath Ketone detection device
Subscribe for More Information
July 16, 2014
07:23 EDTAKERRedChip Companies to hold a virtual conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use